Mednet Logo
Community

What options are available for patients with relapsed/refractory AL amyloidosis after Dara-CyBorD, other than clinical trial?

1 Answer
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · University of Washington, Fred Hutchinson Cancer Research Center
Answered on

No great answers, unfortunately. Lenalidomide still tends to make me a bit nervous in AL amyloidosis, as does carfilzomib in patients with known cardiac involvement. But pom-based regimens are an option, or carfilzomib-based in the appropriate population.

If the patient's BMBx shows t(11;14) by FISH,...

Join for free or sign in to see the full answer